A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients With Osteoarthritis of the Knee or Hip.

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients With Osteoarthritis of the Knee or Hip.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2013

At a glance

  • Drugs Tanezumab (Primary) ; Oxycodone
  • Indications Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 16 Dec 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 22 Nov 2010 Planned end date changed from Oct 2010 to Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top